Managing xerostomia and salivary gland hypofunction: Executive summary of a report from the American Dental Association Council on Scientific Affairs

Journal of the American Dental Association

Volumn 145, Issue 8, 2014, Pages 867-873

  Plemons, Jacqueline M ^a   Al Hashimi, Ibtisam ^b   Marek, Cindy L ^c  

^a Texas M Univ Syst Baylor C   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Saliva; Salivary flow; Xerostomia

Indexed keywords

CHEMICALLY INDUCED; COMPLICATION; HUMAN; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; SALIVARY GLAND; UNITED STATES; XEROSTOMIA;

AMERICAN DENTAL ASSOCIATION; HUMANS; SALIVARY GLANDS; UNITED STATES; XEROSTOMIA;

EID: 84905736433     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.2014.44     Document Type: Article

References (65)

1. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. JADA 2003;134(1):61-69.
2. Jensen SB, Pedersen AM, Vissink A, et al; Salivary Gland Hypofunction/Xerostomia Section; Oral Care Study Group; Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010;18(8):1061-1079.
3. Salaffi F, Carotti M, Iagnocco A, et al. Ultrasonography of salivary glands in primary Sjogren's syndrome: a comparison with contrast sialography and scintigraphy. Rheumatology (Oxford) 2008;47(8):1244-1249.
4. Malouf JG, Aragon C, Henson BS, Eisbruch A, Ship JA. Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. Cancer Detect Prev 2003;27(4):305-310.
5. Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W. The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Support Care Cancer 2008;16(2):171-179.
6. Jensen SB, Pedersen AM, Vissink A, et al; Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010;18(8):1039-1060.
7. Thomson WM, Lawrence HP, Broadbent JM, Poulton R. The impact of xerostomia on oral-health-related quality of life among younger adults. Health Qual Life Outcomes 2006;4:86. doi:10.1186/1477-7525-4-86.
8. de Almeida Pdel V, Gregio AM, Machado MA, de Lima AA, Azevedo LR. Saliva composition and functions: a comprehensive review. J Contemp Dent Pract 2008;9(3):72-80.
9. Mese H, Matsuo R. Salivary secretion, taste and hyposalivation. J Oral Rehabil 2007;34(10):711-723.
10. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis 2003;9(4):165-176.
11. Al-Hashimi I. The management of Sjogren's syndrome in dental practice. JADA 2001;132(10):1409-1417.
12. Navazesh M, Kumar SK. Xerostomia: prevalence, diagnosis, and management. Compend Contin Educ Dent 2009;30(6):326-328, 331-332.
13. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304(4):452-460.
14. Kielbassa AM, Hinkelbein W, Hellwig E, Meyer-Luckel H. Radiation- related damage to dentition. Lancet Oncol 2006;7(4):326-335.
15. Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21(1):1-11.
16. Napenas JJ, Brennan MT, Fox PC. Diagnosis and treatment of xerostomia (dry mouth). Odontology 2009;97(2):76-83.
17. Elsevier/Gold Standard. Clinical Pharmacology (database). www.clinicalpharmacology.com. Accessed Jan. 20, 2013.
18. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral & Maxillofacial Pathology. 3rd ed. St. Louis: Saunders Elsevier; 2009.
19. Villa A, Abati S. Risk factors and symptoms associated with xerostomia: a cross-sectional study. Aust Dent J 2011;56(3):290-295.
20. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and treatment. Dent Clin North Am 2005;49(2): 309-326.
21. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012;12:CD003193. doi:10.1002/14651858. CD003193.pub4.
22. Forte E, Pizzoferrato M, Lopetuso L, Scaldaferri F. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. Eur Rev Med Pharmacol Sci 2012;16(1):25-37.
23. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;(2):CD003735.
24. Ship JA, Fischer DJ. The relationship between dehydration and parotid salivary gland function in young and older healthy adults. J Gerontol A Biol Sci Med Sci 1997;52(5):M310-M319.
25. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987;66(special number):648-653.
26. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 2000;79(9):1652-1658.
27. Kisely S, Quek LH, Pais J, Lalloo R, Johnson NW, Lawrence D. Advanced dental disease in people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2011;199(3):187-193.
28. Yagiela JA, Dowd FJ, Johnson B, Mariotti A, Neidle EA. Introduction to autonomic nervous system drugs. In: Pharmacology and Therapeutics for Dentistry. 6th ed. St. Louis: Mosby Elsevier; 2011:78-81.
29. Yamamoto K, Kurihara M, Matsusue Y, et al. Atrophic change of tongue papilla in 44 patients with Sjogren syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(6):801-805.
30. Turner M, Jahangiri L, Ship JA. Hyposalivation, xerostomia and the complete denture: a systematic review. JADA 2008;139(2):146-150.
31. Fox PC, Eversole LR. Diseases of the salivary glands. In: Silverman S Jr, Eversole LR, Truelove EL, eds. Essentials of Oral Medicine. Hamilton, Ontario, Canada: BC Decker; 2002:260-276.
32. Samnieng P, Ueno M, Shinada K, Zaitsu T, Wright FA, Kawaguchi Y. Association of hyposalivation with oral function, nutrition and oral health in community-dwelling elderly Thai. Community Dent Health 2012;29(1):117-123.
33. Karbach J, Walter C, Al-Nawas B. Evaluation of saliva flow rates, Candida colonization and susceptibility of Candida strains after head and neck radiation. Clin Oral Investig 2012;16(4):1305-1312.
34. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. JADA 1987;115(4): 581-584.
35. Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. JADA 2008;139(5)(suppl):35S-40S.
36. Lofgren CD, Wickstrom C, Sonesson M, Lagunas PT, Christersson C. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health 2012;12:29. doi:10.1186/1472-6831-12-29.
37. Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res 1992;71(7):1363-1369.
38. Ship JA, Fox PC, Baum BJ. How much saliva is enough? 'Normal' function defined. JADA 1991;122(3):63-69.
39. von Bultzingslowen I, Sollecito TP, Fox PC, et al. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(suppl):S57.e1-S57.e15. doi:10.1016/j. tripleo.2006.11.010.
40. Huo AP, Lin KC, Chou CT. Predictive and prognostic value of antinuclear antibodies and rheumatoid factor in primary Sjogren's syndrome. Int J Rheum Dis 2010;13(1):39-47.
41. Shiboski SC, Shiboski CH, Criswell L, et al; Sjogren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64(4):475-487.
42. Caporali R, Bonacci E, Epis O, Bobbio-Pallavicini F, Morbini P, Montecucco C. Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum 2008;59(5):714-720.
43. Al-Hashimi I, Drinnan AJ, Uthman AA, Wright JR, Levine MJ. Oral amyloidosis: two unusual case presentations. Oral Surg Oral Med Oral Pathol 1987;63(5):586-591.
44. Itoh T, Ohashi S, Tsujino T, et al. Primary amyloidosis with dry eyes and dry mouth: a case report. Jpn J Med 1991;30(6):597-599.
45. Mansour MJ, He C, Al-Farra ST, et al. Sarcoidosis and Sjogren's syndrome: clinical and salivary evaluation. J Oral Pathol Med 2013;42(8): 594-599.
46. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004;164(12):1275-1284.
47. Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 2011;41(3):415-423.
48. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004;26(9):796-807.
49. Jenson L, Budenz AW, Featherstone JD, Ramos-Gomez FJ, Spolsky VW, Young DA. Clinical protocols for caries management by risk assessment. J Calif Dent Assoc 2007;35(10):714-723.
50. Ismail AI, Tellez M, Pitts NB, et al. Caries management pathways preserve dental tissues and promote oral health. Community Dent Oral Epidemiol 2013;41(1):e12-e40.
51. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev 2004;13(12):2012-2022.
52. Jarvinen VK, Rytomaa II, Heinonen OP. Risk factors in dental erosion. J Dent Res 1991;70(6):942-947.
53. Lenander-Lumikari M, Loimaranta V. Saliva and dental caries. Adv Dent Res 2000;14(1):40-47.
54. Shiboski CH, Hodgson TA, Ship JA, Schiodt M. Management of salivary hypofunction during and after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(3)(suppl 1):S66.e1-S66.e19.
55. Bartold PM. Dentinal hypersensitivity: a review. Aust Dent J 2006;51(3):212-218.
56. American Dental Association Council on Scientific Affairs. Topical fluoride for caries prevention: full report of the updated clinical recom-mendations and supporting systematic review. http://stage.master. ebd.ada.org/-/media/EBD/Files/Topical-fluoride-for-caries- prevention-2013- update.ashx. Accessed Dec. 23, 2013.
57. Marinho VC, Worthington HV, Walsh T, Clarkson JE. Fluoride varnishes for preventing dental caries in children and adolescents. Cochrane Database Syst Rev 2013;7:CD002279. doi:10.1002/14651858.CD002279. pub2.
58. Redding SW, Zellars RC, Kirkpatrick WR, et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 1999;37(12): 3896-3900.
59. Worthington HV, Clarkson JE, Khalid T, Meyer S, McCabe M. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2010;(7):CD001972. doi:10.1002/14651858.CD001972. pub4.
60. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-535.
61. Scully C, Epstein JB. Xerostomia and hyposalivation in patients with cancer. In: Kirtane MV and de Souza CE, eds. Head and Neck Surgery. Otorhinolaryngology-Head and Neck Surgery Series. New York City: Thieme Medical Publishers; 2013:chap 27.
62. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159(2):174-181.
63. Petrone, D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46(3):748-754.
64. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011;(12):CD008934. doi:10.1002/14651858. CD008934.pub2.
65. Visvanathan V, Nix P. Managing the patient presenting with xerostomia: a review. Int J Clin Pract 2010;64(3):404-407.